Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19073726 | 1.00 | MEN1 (0.45) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL183517 | 0.92 | ALDH1A1 (0.44) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL183757 | 0.88 | MEN1 (0.44) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL20015491 | 0.88 | MEN1 (0.44) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL1224468 | 0.86 | MAPT (0.48) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL1224464 | 0.86 | MAPT (0.48) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL30456334 | 0.86 | MAPT (0.48) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL4167125 | 0.86 | HPGD (0.47) | MEN1ALDH1A1KMT2ATSHRMAPT | |
| SCHEMBL29579744 | 0.86 | MEN1 (0.47) | MEN1ALDH1A1KMT2ATSHRADORA1 | |
| SCHEMBL23979945 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KMT2AMAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4665453-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4658660-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6306882-B1 | FLUOROALKYLPIPERIDINE ESTERS COGNITION ACTIVATORS AND ALZHEIMER'S | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-1000030-A1 | PIPERIDINE OLIGOMERS AND COMBINATORIAL LIBRARIES THEREOF | Phytera Symbion ApS (DK) | 2000-05-17 | — | — | EP | disclosed |
| EP-0989120-A1 | REAGENTS FOR ASSAYING CENTRAL LOCAL ACETYLCHOLINESTERASE ACTIVITY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| US-5965578-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0897303-A4 | — | — | 1999-02-24 | — | — | EP | disclosed |
| EP-0897303-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1999003832-A1 | PIPERIDINE OLIGOMERS AND COMBINATORIAL LIBRARIES THEREOF | PHYTERA SYMBION APS (DK) | 1999-01-28 | — | — | WO | disclosed |
| WO-1997036605-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | MEN1 2354/4885ALDH1A1 3991/4885KMT2A 3631/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 2710/4885ALDH1A1 1397/4885KMT2A 2587/4885 |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | MEN1 397/4885ALDH1A1 4134/4885KMT2A 4403/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | MEN1 428/4885ALDH1A1 907/4885KMT2A 3815/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 721/4885ALDH1A1 3319/4885KMT2A 2075/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | MEN1 3390/4885ALDH1A1 795/4885KMT2A 2665/4885 |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | GPR65, GPR52, GPR68 | MEN1 3756/4885ALDH1A1 2702/4885KMT2A 2700/4885 |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | MEN1 340/4885ALDH1A1 1670/4885KMT2A 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.